Pseudocapsule-Based Resection for Pituitary Adenomas via the Endoscopic Endonasal Approach

Yuefei Zhou; Jialiang Wei; Feng Feng; Jianguo Wang; Pengfei Jia; Shuangwu Yang; Dakuan Gao

doi:10.3389/fonc.2021.812468

Pseudocapsule-Based Resection for Pituitary Adenomas via the Endoscopic Endonasal Approach

Front Oncol. 2022 Jan 17:11:812468. doi: 10.3389/fonc.2021.812468. eCollection 2021.

Authors

Yuefei Zhou¹, Jialiang Wei¹, Feng Feng², Jianguo Wang³, Pengfei Jia¹, Shuangwu Yang¹, Dakuan Gao¹

Affiliations

¹ Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
² Department of Rehabilitation Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
³ Department of Neurosurgery, Shenmu County Hospital, Yulin, China.

Abstract

Introduction: The endoscopic endonasal approach (EEA) is a safe and effective treatment for pituitary adenomas (PAs). Since extracapsular resection (ER) of PAs improves tumor resection and endocrine remission rates, the interface between the pseudocapsule and gland draws increasing attention. However, it is difficult to precisely dissect the tumor along the exact boundary, and complete removal of the tumor increases the risks of normal tissue damage and cerebrospinal fluid (CSF) leakage. In this study, we investigated the extracapsular resection as well as the pseudocapsule histology to evaluate the effectiveness and safety of pseudocapsule-related surgical interventions.

Methods: From December 2017 to December 2019, 189 patients of PAs via EEA in our single center were analyzed retrospectively. The images, operative details, and clinical follow-up of patients were collected. Sixty-four patients underwent pseudocapsule-based ER, and 125 patients also underwent traditional intracapsular resection (IR) with or without intensive excision for FPAs. The clinical characteristics, tumor resection, endocrinological outcomes, and postoperative morbidities of the two groups were compared. Informed consent for publication of our article was obtained from each patient. Histological examination of pseudocapsule was performed using hematoxylin and eosin and reticulin staining.

Results: The gross total recession was 62 (96.9%) in the ER group and 107 (85.6%) cases in the IR group, whereas the endocrine remission rate was 29/31 (93.5%) and 40/53 (75.5%) cases, respectively. Anterior pituitary functions were not aggravated postoperatively in any patient, but transient diabetes insipidus (DI) occurred more in the IR group (64.0%) than in ER (48.4%). Pseudocapsule specimens were obtained in 93 patients, and clusters of small cell aggregation were detected in 11 pseudocapsule specimens (11.8%) whereas other patients showed no remarkable developed pseudocapsule. Intraoperative CSF leak occurred more in the ER group (28.1%) than in the IR group (13.6%), but no difference was seen between two groups postoperatively. No case of intracranial hematoma or pituitary crisis occurred in both groups. After a mean follow-up of 22.8 months, tumor recurrence was observed in 4 (2.1%) cases.

Conclusion: Pseudocapsule-based extracapsular resection of PAs via EEA is an effective and safe procedure to achieve complete resection with high and sustained endocrine remission and without deteriorating pituitary function.

Keywords: cerebrospinal fluid leakage; endoscopic endonasal approach; extracapsular resection; pituitary adenoma; pseudocapsule; skull base reconstruction.